Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Imlygic (talimogene laherparepvec) for the Treatment of Cutaneous, Subcutaneous and Nodal Lesions

Drug (Brand / Generic)

IMLYGIC (Talimogene Laherparepvec)

Company / Licensee

Amgen

Therapy Class

Genetically-modified oncolytic viral

Product Description

Modified herpes simplex virus type 1

Current Indication

Melanoma

Market Sector

Skin disorders

Development Status

Approved in the US
Expand

Go Top